Detailed antibody characterization is a critical component of the discovery process for therapeutic monoclonal antibodies (MAbs). Epitope data informs mechanism-of-action and lead candidate selection, and is valuable for obtaining MAb patent protection. Detailed antibody specificity analysis is crucial for predicting clinical safety by identifying off-target interactions, thereby de-risking antibody therapeutic development.
Integral Molecular has developed innovative solutions such as Shotgun Mutagenesis Epitope Mapping and the Membrane Proteome Array for characterizing antibodies against cell surface targets. These assays are run on the Intellicyt, high-throughput flow cytometry platform to detect MAb binding to proteins natively expressed on cells.
Complete the form below to watch this webinar.